23 May 2013
Keywords: onyx, adenovirus, shows, promise, phase, another, company
Article | 26 May 1997
Another company targeting the p53 gene in cancer therapy is Onyx, whichreported the first results of a Phase I study ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
26 May 1997
30 May 1997
5 May 1997
© 2013 thepharmaletter.com